|
S1021
|
Dasatinib (BMS-354825) |
Dasatinib (BMS-354825, Sprycel) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of ＜1 nM, 0.5 nM and 79 nM, respectively. |
|
|
|
S1006
|
Saracatinib (AZD0530) |
Saracatinib (AZD0530) is a Src inhibitor for c-Src and v-Abl with IC50 of 2.7 nM and 30 nM, respectively. |
|
|
|
S1014
|
Bosutinib (SKI-606) |
Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively. |
|
|
|
S2700
|
KX2-391 |
KX2-391 (KX01) is a highly selective non ATP-competitive Src inhibitor with GI50 of 9-60 nM in cancer cell lines . |
|
|
|
S2202
|
NVP-BHG712 |
NVP-BHG712 is a specific inhibitor of c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM and also inhibits EphB4 and VEGFR2 with ED50 of 25 nM and 4.2 μM, respectively. |
|
|
|
S7008
|
PP2 |
PP2 is Src kinase inhibitor, potently inhibits GST-Src activity with IC50 of 100 nM. |
|
|
